Myk-1
Myk-1 Uses, Dosage, Side Effects, Food Interaction and all others data.
Myk-1, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. Myk-1 nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes making it an effective treatment for tinea cruris and tinea corporis infections.
The function of imidazole derivatives can be attributed to their structural resemblance to purines essential to metabolism.
| Trade Name | Myk-1 |
| Availability | Prescription only |
| Generic | Sulconazole |
| Sulconazole Other Names | Sulconazole |
| Related Drugs | clotrimazole topical, ketoconazole topical, terbinafine, terbinafine topical, cefuroxime, cefadroxil, itraconazole, mupirocin topical, miconazole topical, Bactroban |
| Type | |
| Formula | C18H15Cl3N2S |
| Weight | Average: 397.74 Monoisotopic: 396.0021528 |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | Belgium, Netherlands |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Myk-1 is a topical antifungal agent used for the treatment of tinea cruris, tinea corporis, and tinea versicolor caused by susceptible fungal strains.
Myk-1 solution 1.0% is indicated for the treatment of tinea cruris and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; and for the treatment of tinea versicolor. Effectiveness has not been proven in tinea pedis (athlete’s foot).
Myk-1 is also used to associated treatment for these conditions: Pityriasis versicolor, Tinea Corporis, Tinea Cruris, Tinea Pedis
Toxicity
Myk-1 has been shown to be embryotoxic in a study of rats given 125 times the human dose (in mg/kg) and also resulted in prolonged gestation and dystocia. There are no adequate or controlled studies in pregnant women, therefore sulconazole should only be used during pregnancy if potential benefit justifies potential risk to the fetus.
Food Interaction
No interactions found.Elimination Route
Total sulconazole systemic absorption after topical administration was ~8.71% of the dose.
Elimination Route
About 6.70% of the dose was recovered in urine, and 2.01% in feces over a 7 day collection period. Radioactivity could be detected in both urine and feces at 7 days potentially due to a reservoir effect.
Innovators Monograph
You find simplified version here Myk-1
